MX2020011738A - Uso de calcifediol en pacientes de cirugia bariatrica. - Google Patents
Uso de calcifediol en pacientes de cirugia bariatrica.Info
- Publication number
- MX2020011738A MX2020011738A MX2020011738A MX2020011738A MX2020011738A MX 2020011738 A MX2020011738 A MX 2020011738A MX 2020011738 A MX2020011738 A MX 2020011738A MX 2020011738 A MX2020011738 A MX 2020011738A MX 2020011738 A MX2020011738 A MX 2020011738A
- Authority
- MX
- Mexico
- Prior art keywords
- calcifediol
- bariatric surgery
- surgery patients
- patients
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen métodos y composiciones para tratar a pacientes de cirugía bariátrica y para tratar o prevenir las complicaciones asociadas con dichos pacientes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862652038P | 2018-04-03 | 2018-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011738A true MX2020011738A (es) | 2021-01-08 |
Family
ID=67660407
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010338A MX2020010338A (es) | 2018-04-03 | 2019-04-03 | Uso de calcifediol en pacientes de cirugia bariatrica. |
MX2020011738A MX2020011738A (es) | 2018-04-03 | 2020-09-30 | Uso de calcifediol en pacientes de cirugia bariatrica. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010338A MX2020010338A (es) | 2018-04-03 | 2019-04-03 | Uso de calcifediol en pacientes de cirugia bariatrica. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11590148B2 (es) |
EP (1) | EP3773601A1 (es) |
JP (1) | JP2021520366A (es) |
KR (1) | KR20200140284A (es) |
CN (1) | CN112074275A (es) |
AU (1) | AU2019248829A1 (es) |
CA (1) | CA3094915A1 (es) |
IL (1) | IL277480A (es) |
MX (2) | MX2020010338A (es) |
RU (1) | RU2020135926A (es) |
WO (1) | WO2019193425A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112022019191A2 (pt) | 2020-04-07 | 2022-11-01 | Carbogen Amcis B V | 25-hidroxivitamina d2 e/ou d3 para uso em obesidade |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE056937T2 (hu) | 2006-02-03 | 2022-04-28 | Opko Renal Llc | A D-vitamin elégtelenség és hiány kezelése 25-hidroxivitamin D2-vel és 25-hidroxivitamin D3-mal |
PT2679228T (pt) | 2006-06-21 | 2018-04-16 | Opko Ireland Global Holdings Ltd | Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d |
PT2148684E (pt) | 2007-04-25 | 2013-04-19 | Cytochroma Inc | Método de tratamento para a insuficiência e deficiência de vitamina d |
WO2008134523A1 (en) | 2007-04-25 | 2008-11-06 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
KR101959952B1 (ko) * | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
WO2009124210A1 (en) | 2008-04-02 | 2009-10-08 | Cytochroma Inc. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
US20100093678A1 (en) * | 2008-10-10 | 2010-04-15 | The University Of Georgia Research Foundation, Inc | Compositions and methods of the treatment of obesity and osteoporosis |
US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
JP6385126B2 (ja) | 2014-05-02 | 2018-09-05 | キヤノン株式会社 | 固体撮像装置 |
WO2016205245A1 (en) * | 2015-06-14 | 2016-12-22 | Technology Recovery Systems Llc | Transdermal delivery formulation |
CA3018019A1 (en) * | 2016-03-28 | 2017-10-26 | Opko Ireland Global Holdings, Limited | Methods of vitamin d treatment |
-
2019
- 2019-04-03 CA CA3094915A patent/CA3094915A1/en active Pending
- 2019-04-03 AU AU2019248829A patent/AU2019248829A1/en active Pending
- 2019-04-03 KR KR1020207029309A patent/KR20200140284A/ko not_active Application Discontinuation
- 2019-04-03 JP JP2020554174A patent/JP2021520366A/ja active Pending
- 2019-04-03 MX MX2020010338A patent/MX2020010338A/es unknown
- 2019-04-03 CN CN201980027629.6A patent/CN112074275A/zh active Pending
- 2019-04-03 US US16/374,348 patent/US11590148B2/en active Active
- 2019-04-03 RU RU2020135926A patent/RU2020135926A/ru unknown
- 2019-04-03 EP EP19755426.4A patent/EP3773601A1/en active Pending
- 2019-04-03 WO PCT/IB2019/000572 patent/WO2019193425A1/en unknown
-
2020
- 2020-09-21 IL IL277480A patent/IL277480A/en unknown
- 2020-09-30 MX MX2020011738A patent/MX2020011738A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2020010338A (es) | 2020-11-13 |
KR20200140284A (ko) | 2020-12-15 |
EP3773601A1 (en) | 2021-02-17 |
JP2021520366A (ja) | 2021-08-19 |
WO2019193425A1 (en) | 2019-10-10 |
US20190298744A1 (en) | 2019-10-03 |
AU2019248829A1 (en) | 2020-10-22 |
RU2020135926A (ru) | 2022-05-04 |
US11590148B2 (en) | 2023-02-28 |
CN112074275A (zh) | 2020-12-11 |
CA3094915A1 (en) | 2019-10-10 |
IL277480A (en) | 2020-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551923A1 (en) | Methods and compositions for treating cancer | |
WO2017096309A8 (en) | Methods of treatment of malignancies | |
MX2020013468A (es) | Anticuerpos il-11ra. | |
CA3010887A1 (en) | Axl-specific antibody-drug conjugates for cancer treatment | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
MX2019009753A (es) | Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos. | |
MX2018007266A (es) | Combinaciones para el tratamiento del cancer. | |
PH12018502491A1 (en) | Cancer treatments | |
EP3801477A4 (en) | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF TISSUE CALCIFICATION | |
MX2021006884A (es) | Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina. | |
SG10201806020VA (en) | Electroactive bioadhesive compositions | |
MX2022001004A (es) | Inhibidores de enzimas. | |
MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
MX2020009733A (es) | Composiciones. | |
NZ756936A (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
GB2558315A (en) | Patterned surfaces | |
PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
MX2021010665A (es) | Metodos de tratamiento de amiloidosis al. | |
MX2019012892A (es) | Composicion topica para tratar la rosacea y metodo para tratar la rosacea con la misma. | |
MX2020011738A (es) | Uso de calcifediol en pacientes de cirugia bariatrica. | |
MX2020001632A (es) | Composiciones que comprenden cepas bacterianas. | |
PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
WO2020086954A3 (en) | Treatments for charcot-marie-tooth disease |